TNFRSF4 (Ivuxolimab Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA023981MB11HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:TNFRSF4(Ivuxolimab Biosimilar Antibody)重組單克隆抗體是一種針對(duì)腫瘤壞死因子受體超家族成員4(TNFRSF4,又稱(chēng)OX40)的生物制劑,主要用于生命科學(xué)研究領(lǐng)域。該抗體通過(guò)特異性結(jié)合TNFRSF4靶點(diǎn),可在體外和體內(nèi)實(shí)驗(yàn)中調(diào)控免疫細(xì)胞功能,為免疫學(xué)、腫瘤學(xué)等研究提供工具。 作為研究用試劑,該抗體具有高純度和高特異性的特點(diǎn),經(jīng)重組DNA技術(shù)在哺乳動(dòng)物細(xì)胞中表達(dá)制備,確保了批次間的一致性和實(shí)驗(yàn)結(jié)果的可靠性。其作用機(jī)制主要通過(guò)激活或阻斷OX40信號(hào)通路,研究該通路在T細(xì)胞增殖、分化及免疫調(diào)節(jié)中的作用,為探索自身免疫性疾病、腫瘤免疫治療等領(lǐng)域的分子機(jī)制提供支持。 在科研應(yīng)用中,該抗體可用于某些實(shí)驗(yàn),幫助研究人員分析TNFRSF4在不同組織和細(xì)胞中的表達(dá)分布,以及其與疾病發(fā)生發(fā)展的關(guān)聯(lián)。同時(shí),通過(guò)體外細(xì)胞培養(yǎng)和動(dòng)物模型實(shí)驗(yàn),可深入探究OX40介導(dǎo)的免疫應(yīng)答機(jī)制,為開(kāi)發(fā)新型免疫治療策略提供理論基礎(chǔ)。 該產(chǎn)品僅作為科研工具使用,不可用于臨床診斷或治療。使用時(shí)需嚴(yán)格遵循實(shí)驗(yàn)操作規(guī)范,根據(jù)具體研究需求優(yōu)化抗體濃度和反應(yīng)條件,以獲得準(zhǔn)確的實(shí)驗(yàn)數(shù)據(jù)。其研發(fā)與應(yīng)用有助于推動(dòng)免疫調(diào)控機(jī)制研究的深入,為相關(guān)疾病的基礎(chǔ)研究和藥物開(kāi)發(fā)提供重要支持。
-
Uniprot No.:
-
基因名:
-
別名:Anti-OX40 Antibody PF-04518600 research-grade biosimilar; anti-OX40R-11D4 research-grade biosimilar; B110 research-grade biosimilar; PF-04518600 research-grade biosimilar; PF-8600 research-grade biosimilar ;TNFRSF4 antibody; TXGP1L antibody; Tumor necrosis factor receptor superfamily member 4 antibody; ACT35 antigen antibody; OX40L receptor antibody; TAX transcriptionally-activated glycoprotein 1 receptor antibody; CD antigen CD134 antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human TNFRSF4 protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類(lèi)型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說(shuō)明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity.; (Microbial infection) Acts as a receptor for human herpesvirus 6B/HHV-6B.
-
基因功能參考文獻(xiàn):
- High OX40 expression in Ovarian carcinoma is correlated with chemosensitivity and improved recurrence free survival in Ovarian carcinoma . Patients might therefore benefit from a second line therapy. PMID: 29661166
- Increased OX40 expression is associated with gastric cancer. PMID: 29529339
- this study demonstrates that cSCCs contain an abundance of Tregs which can suppress tumoral effector T cell function and that activation of the costimulatory receptor OX40 enhances tumoral T cell responses. PMID: 27034329
- OX40 expression on T cells was positively associated with obesity in humans. PMID: 28612217
- Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection. PMID: 28892135
- this study investigated whether CD134 is preferentially expressed on CD4 T cells in drug-induced hypersensitivity syndrome . PMID: 27174092
- blocking of both OX-40L and 4-1BBL reversed radiation-enhanced T-cell killing of human tumor targets as well as T-cell survival and activation. PMID: 26872462
- Low OX40 expression is associated with colorectal cancer. PMID: 26439988
- OX40 and its ligand are co stimulators for T lymphocytes. PMID: 26755473
- These studies provide the first direct evidence that ligation of tumour necrosis factor superfamily members and their cognate receptors is important for the control of viral lytic replication. PMID: 26467721
- Malaria patients and Plasmodium-infected rodents exhibit enhanced expression of the co-stimulatory receptor OX40 on CD4 T cells, which is abrogated following coordinate PD-1 co-inhibitory pathways, which are also upregulated during malaria. PMID: 25891357
- Identified two key amino acid residues within CD134 that are required for its interaction with herpesvirus 6B (HHV-6B) and for HHV-6B entry into cells. One of the residues (K79) allows access of the HHV-6B ligand to CD134. PMID: 26202244
- TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells PMID: 25148371
- High expression of OX40 is associated with type 1 diabetes. PMID: 24797972
- A cysteine-rich domain of CD134 that is critical for binding to the HHV-6B glycoprotein gH/gL/gQ1/gQ2 complex and HHV-6B infection. PMID: 25008928
- cirrhotic and hepatocellular carcinoma fragments moderately and highly infiltrated by Tregs, respectively, expressing OX40 PMID: 24756990
- data show that Ag-specific CD4(+) CD25(+) CD134(+) CD39(+) T cells are highly enriched for Treg cells, form a large component of recall responses and maintain a Treg-cell-like phenotype upon in vitro expansion. PMID: 24752698
- expression is associated with breast cancer in a stage dependent manner PMID: 23502335
- OX40 signals regulate CD8 T cell survival at least in part through maintaining expression of the anti-apoptotic molecule A1 PMID: 23936461
- Hyperactivation of the Akt pathway in Teff cells from children with lupus nephritis is associated with reduced induction of TRAF6 and up-regulation of OX40, which may cause Teff cell resistance to Treg cell-mediated suppression. PMID: 23896866
- This study identified OX40 as a key molecule and biomarker for rapid progression of HTLV-1-associated myelopathy/tropical spastic paraparesis. PMID: 23651542
- CD134 is a cellular receptor specific for human herpesvirus-6B entry. PMID: 23674671
- Head and neck cancer patients have decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB. PMID: 22204816
- CD137 activity is directly proportional to colorectal cancer stage. Surgical resection of the tumor results in increased CD134 and CD137 expression PMID: 22343199
- We show that the inflammatory and cytotoxic function of CD4(+)CD28(null) T cells can be inhibited by blocking OX40 and 4-1BB costimulatory receptors. PMID: 22282196
- PAPP-A level was significantly related to soluble and membrane-bound OX40L in patients with ACS. PMID: 21111564
- Compared with control group, the expression of OX40 and Bcl-2 was significantly higher in allergic rhinitis. PMID: 19253527
- Transgenic OX40 forms a signaling complex in T cells that contains phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB). PMID: 21289304
- High OX40 expression may be associated with malignant transformation, progression, invasion and metastasis in breast cancer biology. PMID: 20634005
- Possible proinflammatory effects of OX40L on the pathogenesis of atherosclerois. PMID: 21086790
- This study has shown that activation of OX40 induces CCL20 expression in the presence of antigen stimulation. PMID: 20400327
- The rs2298212G/A polymorphism in OX40 gene may be associated with the severity of coronary atherosclerotic disease. PMID: 20376799
- Data suggest the role of Perforin + cytotoxic T lymphocytes and CD134+ cells in the pathogenesis of autoimmunity of SLE. PMID: 20306696
- Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. PMID: 12296857
- CD134 positive cells are identified within inflammatory lesions of active multiple sclerosis (MS), acute MS and chronic active MS as well as in acute disseminated leukoencephalitis patients. PMID: 14644025
- Mutagenesis showed that Asp60 and Asp62 are required for interaction with FIV, and modeling studies localized these two residues to the outer edge of domain 1 PMID: 15592478
- The expression of CD134 was markedly higher, compared to CD137, both on the day of the surgery and ten days after colorectal cancer surgery. PMID: 15638367
- Deficiencies in OX40 and CD30 signals were additive, secondary Ab responses were ablated.OX40/CD30 double-knockout OTII transgenic T cells fail to survive compared with normal T cells when cocultured with CD4(+)CD3(-) cells in vitro. PMID: 15778343
- Decrease in OX40 expression posttransplant includes the defective reconstitution of Treg cells, and the active inhibition of gene transcription by cyclosporine. PMID: 15808546
- stimulation of OX40/4-1BB rendered cells sensitive to apoptosis induced by TNF-alpha and reduced activation of NF-kappaB. OX40/4-1BB stimulation repressed the mitogen response in activated CD25+CD4+ T cells and preactivated CD8+ T cells PMID: 15941918
- CD3+ T lymphocytes co-expressing CD134 and CD137 antigens on peripheral blood revealed an increased percentages of OX-40/CD137 positive cells in patients with Graves' disease (p<0.025) compared to the controls. PMID: 16232366
- The relevance of these findings is supported by the vital functions fulfilled by OX40 in mammals as reflected by the high level of evolutionary conservation. PMID: 16329997
- The coexpression of CD25 and the costimulatory molecule CD134 on memory T-cells provides a novel marker for type 1 diabetes-associated T-cell immunity. PMID: 16380476
- OX40 ligation on CD4(+) T cells represents a potentially novel immunotherapeutic strategy that should be investigated to treat and prevent persistent virus infections, such as HIV-1 infection. PMID: 16456009
- OX40 is induced transiently on CD8(+) T cells upon activation and its signals contribute to both clonal expansion and functional reinforcement PMID: 16750861
- In the present study we found that costimulation via OX40 and TNF-R in OX40-expressing HIV-1-infected T cell lines leads to a marked reduction of HIV-1 production associated with rapid cell death. PMID: 18327975
- The expression of OX40 on CD4+ T cells in sentinel lymph nodes draining primary melanomas decreased withe more advanced tumor features, suggesting an immunosuppressive effect. PMID: 18374895
- Activity of OX40 ligand is enhanced by oligomerization and cell surface immobilization. PMID: 18397322
- the frequency of the most frequent haplotype, C-C-A-A, was significantly lower and that of the second most frequent, C-T-G-A, was significantly higher in hypertensive subjects than in controls. This difference was observed only in female patients PMID: 18398332
- These data offer a novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL. PMID: 18645038
顯示更多
收起更多
-
相關(guān)疾?。?/div>Immunodeficiency 16 (IMD16)亞細(xì)胞定位:Membrane; Single-pass type I membrane protein.數(shù)據(jù)庫(kù)鏈接:
Most popular with customers
-
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-















